CA2405072A1 - Gel compositions containing metronidazole - Google Patents

Gel compositions containing metronidazole Download PDF

Info

Publication number
CA2405072A1
CA2405072A1 CA002405072A CA2405072A CA2405072A1 CA 2405072 A1 CA2405072 A1 CA 2405072A1 CA 002405072 A CA002405072 A CA 002405072A CA 2405072 A CA2405072 A CA 2405072A CA 2405072 A1 CA2405072 A1 CA 2405072A1
Authority
CA
Canada
Prior art keywords
compositions containing
gel compositions
metronidazole
containing metronidazole
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002405072A
Other languages
French (fr)
Other versions
CA2405072C (en
Inventor
Yunik Chang
Gordon J. Dow
Arturo Angel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Pharmaceutical Sciences Inc
Original Assignee
Dow Pharmaceutical Sciences
Yunik Chang
Gordon J. Dow
Arturo Angel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences, Yunik Chang, Gordon J. Dow, Arturo Angel filed Critical Dow Pharmaceutical Sciences
Publication of CA2405072A1 publication Critical patent/CA2405072A1/en
Application granted granted Critical
Publication of CA2405072C publication Critical patent/CA2405072C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Abstract

An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75 %. The solution contains the solubility enhancer hydroxypropyl-betacyclodextrin and may additionally contain niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed.
CA002405072A 2000-07-13 2001-06-19 Gel compositions containing metronidazole Expired - Fee Related CA2405072C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/615,169 US6468989B1 (en) 2000-07-13 2000-07-13 Gel compositions containing metronidazole
US09/615,169 2000-07-13
PCT/US2001/019644 WO2002006349A1 (en) 2000-07-13 2001-06-19 Gel compositions containing metronidazole

Publications (2)

Publication Number Publication Date
CA2405072A1 true CA2405072A1 (en) 2002-01-24
CA2405072C CA2405072C (en) 2007-08-28

Family

ID=24464287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405072A Expired - Fee Related CA2405072C (en) 2000-07-13 2001-06-19 Gel compositions containing metronidazole

Country Status (10)

Country Link
US (1) US6468989B1 (en)
EP (1) EP1303541B1 (en)
JP (1) JP4130358B2 (en)
AR (1) AR030245A1 (en)
AT (1) ATE506950T1 (en)
AU (1) AU2001269937A1 (en)
CA (1) CA2405072C (en)
DE (1) DE60144520D1 (en)
ES (1) ES2365322T3 (en)
WO (1) WO2002006349A1 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605751B1 (en) 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
US8679523B2 (en) 1999-12-30 2014-03-25 Kimberly-Clark Worldwide, Inc. Oxygen-delivery closed cell foam matrix for wound treatment
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
CN1678277B (en) 2002-07-29 2010-05-05 艾克里麦德公司 Methods and compositions for treatment of dermal conditions
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7645803B2 (en) 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050090564A1 (en) * 2003-10-28 2005-04-28 Wegener Paul T. Compositions and treatments of bacterial vaginosis
BRPI0511519A (en) 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In method for treating or preventing an inflammatory skin disorder and the symptoms associated with it, topical composition suitable for treating or preventing the symptoms of an inflammatory dermatological disorder, and packaging for a topical composition
FR2887149B1 (en) 2005-06-17 2007-08-03 Galderma Sa PROCESS FOR SOLUBILIZING THE METRONIDAZOLE
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
WO2006015317A2 (en) 2004-07-30 2006-02-09 Acrymed, Inc. Antimicrobial devices and compositions
IN266973B (en) 2004-07-30 2007-07-06 Kimberly Clark Co
EP1809264B1 (en) 2004-09-20 2016-04-13 Avent, Inc. Antimicrobial amorphous compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
FR2890560B1 (en) * 2005-09-13 2011-06-24 Galderma Sa METRONIDAZOLE DERMATOLOGICAL FOAMS AND EMULSIONS FOR THEIR PREPARATION
FR2890559B1 (en) * 2005-09-13 2011-06-24 Galderma Sa DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION
US8293965B2 (en) 2006-04-28 2012-10-23 Kimberly-Clark Worldwide, Inc. Antimicrobial site dressings
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
BRPI0822095A2 (en) 2007-12-21 2014-10-07 Galderma Lab Inc METHOD FOR REDUCING BLEEDING AND / OR HEMATOMA IN A PATIENT
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
MX359879B (en) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Topical tetracycline compositions.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
MX2012010824A (en) 2010-03-26 2012-10-10 Galderma Res & Dev Improved methods and compositions for safe and effective treatment of erythema.
AU2011231544B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
WO2012001065A2 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
WO2012052479A2 (en) 2010-10-21 2012-04-26 Galderma S.A. Brimonidine gel compositions and methods of use
US8946276B2 (en) * 2011-06-28 2015-02-03 Watson Laboratories, Inc. High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
US9744168B2 (en) 2011-10-19 2017-08-29 Galderma Laboratories, Inc. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
WO2013057580A1 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method for treating capillary hemangiomas
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (en) 2011-11-10 2015-08-10 TREATMENT OF SKIN DISEASES AND STATES
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
AU2014260033B2 (en) 2013-05-02 2019-06-27 Medical Technology Research Inc. Antimicrobial compositions and methods of making the same
AU2014326298B2 (en) 2013-09-26 2019-07-04 Galderma Holding SA Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
WO2017172761A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN110314133A (en) * 2019-06-28 2019-10-11 石家庄四药有限公司 A kind of metronidazole injection and preparation method thereof
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
DE3346123A1 (en) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
WO1988006888A1 (en) * 1987-03-20 1988-09-22 Curatek Pharmaceuticals, Inc. Novel topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
TW200402B (en) 1990-08-13 1993-02-21 Senju Pharma Co
CA2112112A1 (en) * 1991-06-24 1993-01-07 Ann J. Brothers Hormone-secreting cells maintained in long-term culture
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH07157440A (en) * 1993-10-15 1995-06-20 Takeda Chem Ind Ltd Composition for medicine
FR2722098B1 (en) 1994-07-06 1996-08-23 Cird Galderma NEW MEDICINES BASED ON METRO-NIDAZOLE OR A SYNERGETIC MIXTURE OF METRONIDAZOLE AND CLINDAMYCIN
EP1007049A1 (en) * 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US5989523A (en) * 1998-03-20 1999-11-23 Fitzjarrell; Edwin A. Topical spray for treating acne containing niacinamide and NaPCA
BR9913857A (en) * 1998-09-17 2001-06-12 Lilly Co Eli Protein formulations
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole

Also Published As

Publication number Publication date
JP4130358B2 (en) 2008-08-06
JP2004515463A (en) 2004-05-27
EP1303541A1 (en) 2003-04-23
ES2365322T3 (en) 2011-09-29
AR030245A1 (en) 2003-08-13
DE60144520D1 (en) 2011-06-09
EP1303541A4 (en) 2007-01-31
WO2002006349A1 (en) 2002-01-24
US6468989B1 (en) 2002-10-22
EP1303541B1 (en) 2011-04-27
CA2405072C (en) 2007-08-28
ATE506950T1 (en) 2011-05-15
AU2001269937A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
CA2405072A1 (en) Gel compositions containing metronidazole
EP2292771A3 (en) Sense mRNA therapy
AU2002239991A1 (en) Electronic procurement ("e-procurement")
HK1152714A1 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer steap-1
MXPA02005797A (en) Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations.
WO2004066805A3 (en) In vivo device for improving diastolic ventricular function
WO2003045878A3 (en) 2,w-diaminocarboxylic acid compounds
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2002044156A3 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2003087306A8 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
HUP9701437A3 (en) Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive enzymes, pharmaceutical compns. and kits
EP1050532A3 (en) Preparation of s,s and r,s amino acid isosteres
JO3106B1 (en) Solid preparation comprising pioglitazone, glimepiride and a polyoxtethylene sorbitan fatty acid ester
WO2000053776A3 (en) Human kallikrein-like genes
AU2002366357A1 (en) Identification of essential genes of cryptococcus neoformans and methods of use
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
EP1501465A4 (en) Vectors having both isoforms of beta-hexosaminidase
PT1537140E (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2004092727A3 (en) Compound libraries and methods for drug discovery
MXPA03011128A (en) Flavour and fragrance compositions.
EP1409710A4 (en) Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
CA2207120A1 (en) Use of theophylline derivatives for the treatment and prophylaxis of states of shock, novel xanthine compounds and processes for their preparation
Chiu et al. Implementation of Taiwan relations act: An examination after twenty years
AU3556800A (en) Expression of dna or proteins in (c. elegans)
DK1156829T3 (en) Stable formulation containing fumagillin

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160620